期刊文献+

基于PK/PD模型优化加替沙星胃肠道给药方案 被引量:1

Optimizing Dosage Regimen of Gatifloxacin by Gastrointestinal Tract Based on Pharmacokinetic-pharmacodynamic Model
下载PDF
导出
摘要 目的通过建立药代动力学/药效学(PK/PD)模型确定加替沙星胃肠道最佳给药方案。方法募集40名健康志愿者按3种给药方案(分别为:400mg qd、200mg bid、100mg qid)口服加替沙星片,HPLC-UV法测定血药浓度,求出药代动力学参数即加替沙星对敏感菌的抗菌活性MIC90;用DAS软件拟合出不同给药方案时%T>MIC90,确定加替沙星胃肠道最佳给药方案。结果根据建立的PK/PD模型拟合结果,3种给药方案的%T>MIC90分别为31.6%、42.6%和17.8%。结论优化的加替沙星胃肠道给药方案为200mg,bid,此时%T>MIC90符合35%~55%的理想比值。 Objective To study dosage regimen of gatifloxacin by gastrointestinal tract based on pharmacokinetic-pharmacodynamic model. Methods The study was conducted in 40 healthy vounteers. After receiving a single dose of 400 mg gatifloxacin tablets on the three dosage regimens ( 400mg one time a day, 200rag two times a day, 100 mg four times a day ). Blood drug concentrations were determined by HPLC-UV and the pharmaeokinetic parameters were calculated by DAS program. The pharmacodynamic parameters were minimal inhibitory concentration ( MIC90 ) of sensitive bacteria. The pharmacokinetic and pharmacodynamic parameters were simulated by DAS program for %T 〉 MIC90 value, and reasonable dosage regimen was calculated. Results The PK/PD model established by DAS suggested that the value of %T 〉 MIC90 of three dosage regimens were 31.6%, 42.6% and 17.8%, respectively. Conclusion To achieve the ideal value 35%-55% of T 〉 MIC90 and more effectiveness, gatifloxacin may be taken orally 200 mg two times a day.
作者 谭兴华
出处 《中国现代医生》 2011年第27期59-61,共3页 China Modern Doctor
关键词 药代动力学/药效学模型 加替沙星 高效液相色谱法 给药方案 Pharmacokinetic-pharmacodynamic model Gatifloxacin HPLC Dosage regimen
  • 相关文献

参考文献7

二级参考文献38

  • 1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 2Xiao YH.Research and clinical application of antibiotic pharmacodynamics (1). Chin J Clin Pharmacol, 2002,4:310-316.肖永红.抗生素药效学研究与临床应用(1). 中国临床药理杂志, 2002,4:310-316.
  • 3Ambrose PG, Quintiliani R, Nightingale CH, et al. Continuous vs intermittent infusion of cefuroxime for the treatment of community aquired pneumonia. Infect Dis Clin Prac ,1998,7:463-470.
  • 4Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agent Chemother, 1995,39:650-655.
  • 5Hosaka M, Yasue T, Fukuda H, et al. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone[J].Antimicrob Agents Chemother, 1992,36:2108-2117
  • 6Hirai K, Yasue T, Hosaka M,et al. In vitro antibacterial activity of AM-1155[J]. Drugs,1993, 45(Suppl 3):182-183
  • 7Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone[J]. Antimicrob Agents Chemother, 1994,38: 594-601
  • 8Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clin Infect Dis, 2000,31(Supp1 2):S51-S58
  • 9Nakashima M, Uematsu T, Kosuge K, et al. Single and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans[J]. Antimicrob Agents Chemother,1995,39: 2635-2640
  • 10Brece J, Skuba K, Grasela DM. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone[J]. J Res Dis,1999,20(Suppl): S70-S76

共引文献135

同被引文献34

引证文献1

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部